History of macrolide use in pediatrics

Pediatric Infectious Disease Journal

Volumn 16, Issue 4, 1997, Pages 427-431

  Klein, Jerome O ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

azalide; Azithromycin; clarithromycin; erythromycin

Indexed keywords

AZITHROMYCIN; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; DIGOXIN; ERYTHROMYCIN; MACROLIDE; TERFENADINE; THEOPHYLLINE; WARFARIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OTITIS MEDIA; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; TONSILLITIS; TOPICAL DRUG ADMINISTRATION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; DRUG INTERACTIONS; ERYTHROMYCIN; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HISTORY, 20TH CENTURY; HUMANS; INFANT; INFANT, NEWBORN; MICROSCOPY, ELECTRON; PHAGOCYTES; PHAGOCYTOSIS;

EID: 0030955113     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199704000-00025     Document Type: Conference Paper

References (30)

1. Steigbigel NH. Macrolides and clindamycin. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:334-46.
2. McCormick WM, Rosner B, Lee YH, et al. Effect on birth weight of erythromycin treatment of pregnant women. Obstet Gynecol 1987;69:202-7.
3. Sabath LD, Gerstein DA, Loder PB, et al. Excretion of erythromycin and its enhanced activity in urine against Gram-negative bacilli with alkalinization. J Lab Clin Med 1968;72:916-23.
4. Washington JA II, Wilson WR. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (first of two parts). Mayo Clin Proc 1985;60:189-203.
5. Washington JA II, Wilson WR. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (second of two parts). Mayo Clin Proc 1985;60:271-8.
6. Catnach SM, Fairclough PD. Erythromycin and the gut. Gut 1992;33:397-401.
7. Itoh Z, Suzuki T, Nakaya M, Inowe M, Arai H, Wakabayashi K. Structure-activity relation among macrolide antibiotics in initiation of interdigestive migrating contractions in the canine gastrointestinal tract. Am J Physiol 1985;11:G320-5.
8. Braun P. Hepatotoxicity of erythromycin. J Infect Dis 1969; 119:300-6.
9. Eckman MR, Johnson T, Riess R. Partial deafness after erythromycin [Letter]. N Engl J Med 1975;292:649.
10. Reisz G, Pingleton SK, Melethil S, Ryan PB. The effect of erythromycin on theophylline pharmacokinetics in chronic bronchitis. Ann Rev Respir Dis 1983;127:581-4.
11. Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992;26:46-55.
12. Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985;10:63-79.
13. Kirst HA, Sides GD. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother 1989;33:1413-8.
14. Fish DN, Gotfried MH, Danziger LH, Rodvold KA. Penetration of clarithromycin into lung tissues from patients undergoing lung resection. Antimicrob Agents Chemother 1994;38: 876-8.
15. Physicians' desk reference®. 50th ed. Montvale, NJ: Medical Economics Data, 1996.
16. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl A):73-82.
17. Data on file. New York: Pfizer Inc, 1996.
18. Nahata MC. Pharmacokinetics of azithromycin in pediatric patients: comparison with other agents used for treating otitis media and streptococcal pharyngitis. Pediatr Infect Dis J 1995;14:S39-44.
19. Anderson R, Joone G, van Rensburg CEJ. An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother 1988;22:923-33.
20. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
21. Guay DRP. Macrolide antibiotics in paediatric infectious diseases. Drugs 1996;51:515-36.
22. Pass RJ. Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. Antimicrob Agents Chemother 1993;37: 2080-6.
23. McCracken GH Jr. Microbiologic activity of the newer macrolide antibiotics. Pediatr Infect Dis J 1997;16:432-7.
24. Hopkins SJ. Clinical toleration and safety of azithromycin in adults and children. Rev Contemp Pharmacother 1994;5: 383-9.
25. Craft JC, Siepman N. Overview of the safety profile of clarithromycin suspension in pediatric patients. Pediatr Infect Dis J 1993;12:S142-7.
26. Wallace MR, Miller LK, Nguyen MT, Shields AR. Ototoxicity with azithromycin. Lancet 1994;343:241.
27. Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high dose clarithromycin among elderly patients. Diagn Microb Infect Dis 1993;16:215-21.
28. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31.
29. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J Antimicrob Chemother 1996; 37(Suppl C):133-42.
30. Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994;7:148-56.